Overview
Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Alex Karlsson-Parra, INTERIM CEO.
Phone: +46(0)8 732 8400
Email: ir@immunicum.com
CEO statement, Q3 report 2019
“We have concluded a very successful third quarter with the announcement of positive topline results from the phase II MERECA study with ilixadencel, our allogeneic, off-the-shelf, cell-based therapy. Ilixadencel demonstrated initial signs of efficacy and has maintained a positive safety and tolerability profile. Based on these results we can begin advancing ilixadencel towards late-stage clinical development.”
To read the full report, please click here
Investor Downloads
